SOPHiA GENETICS SA (SOPH): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
SOPHiA GENETICS SA (SOPH) Bundle
In the rapidly evolving field of genomics, SOPHiA GENETICS SA (SOPH) stands out with its innovative business model that leverages advanced technology to enhance diagnostic accuracy. This Business Model Canvas highlights key elements such as strategic partnerships with hospitals and pharmaceutical companies, proprietary software development, and a focus on personalized customer relationships. Dive deeper to explore how SOPHiA GENETICS is reshaping the landscape of genomic data analysis and driving value for its diverse customer segments.
SOPHiA GENETICS SA (SOPH) - Business Model: Key Partnerships
Collaborations with hospitals and laboratories
SOPHiA GENETICS collaborates with numerous hospitals and laboratories worldwide to enhance its data-driven medicine initiatives. As of September 2024, the company reported partnerships with over 1,000 healthcare institutions globally. These collaborations enable access to diverse genomic and clinical data, facilitating the development of its SOPHiA DDM Platform.
Partnerships with pharmaceutical companies
The company has formed strategic alliances with major pharmaceutical firms to support clinical trials and drug development. Notably, SOPHiA GENETICS has partnered with companies such as Merck and Novartis, focusing on utilizing their genomic data capabilities to advance precision medicine. The financial impact of these partnerships includes a revenue contribution of approximately $15 million in the nine months ended September 30, 2024, from pharmaceutical collaborations.
Alliances with technology providers
SOPHiA GENETICS has established partnerships with technology providers to enhance its analytical capabilities. Collaborations with companies such as Amazon Web Services (AWS) and Illumina allow SOPHiA to leverage cloud computing and advanced sequencing technologies. These partnerships have been instrumental in driving the scalability of their platform, with an estimated operational cost reduction of 20% attributed to cloud technologies as of 2024.
| Partnership Type | Partner | Focus Area | Revenue Contribution (USD) |
|---|---|---|---|
| Hospital Collaboration | Multiple (1,000+ institutions) | Data Sharing | N/A |
| Pharmaceutical Partnership | Merck | Clinical Trials | $15 million |
| Pharmaceutical Partnership | Novartis | Drug Development | $15 million |
| Technology Alliance | Amazon Web Services | Cloud Computing | 20% cost reduction |
| Technology Alliance | Illumina | Sequencing Technology | N/A |
SOPHiA GENETICS SA (SOPH) - Business Model: Key Activities
Development of the SOPHiA DDM Platform
The SOPHiA DDM Platform is at the core of SOPHiA GENETICS' operations. As of September 30, 2024, the Company reported revenues from the SOPHiA DDM Platform amounting to $46.3 million for the nine months ended, compared to $44.3 million for the same period in 2023. The platform enables healthcare providers to analyze and interpret complex genomic data efficiently, thereby supporting data-driven medicine.
Data analysis and interpretation services
SOPHiA GENETICS offers comprehensive data analysis and interpretation services, which are integral to its value proposition. The revenue generated from these services contributes significantly to the overall financial performance. For the three months ended September 30, 2024, total revenue was $15.85 million, with data analysis services being a primary revenue driver. The Company reported a gross profit of $10.65 million during the same period, indicating a strong demand for its analytical capabilities.
Continuous research and innovation in genomic data
The commitment to continuous research and innovation is evident in SOPHiA GENETICS' financial allocations. The Company incurred $25.2 million in research and development costs for the nine months ended September 30, 2024. This investment underlines the emphasis on enhancing the SOPHiA DDM Platform and expanding its genomic data analysis capabilities.
| Activity | Details | Financial Impact (USD thousands) |
|---|---|---|
| SOPHiA DDM Platform Revenue | Revenue generated from the SOPHiA DDM Platform | $46,302 (2024) |
| Data Analysis Services | Comprehensive genomic data interpretation services | $15,853 (Q3 2024) |
| Research and Development Costs | Investment in continuous innovation and platform enhancement | $25,223 (2024) |
SOPHiA GENETICS SA (SOPH) - Business Model: Key Resources
Proprietary software technology
SOPHiA GENETICS has developed the SOPHiA DDM Platform, a cloud-native software solution that facilitates data-driven medicine. As of September 30, 2024, the platform has generated a revenue of $46.3 million for the nine-month period, contributing significantly to the company's overall revenue of $47.4 million during the same period.
Skilled workforce in genomics and data science
The company employs a highly skilled workforce with expertise in genomics and data science, essential for developing and enhancing the SOPHiA DDM Platform. As of September 30, 2024, the company reported a total workforce of approximately 240 employees.
Robust data infrastructure and cloud capabilities
SOPHiA GENETICS utilizes advanced data infrastructure and cloud capabilities to support its platform. The company has invested in a robust cloud-based architecture, enabling the processing of complex multimodal datasets. As of September 30, 2024, the company reported total assets of $177.6 million, including significant investments in technology and infrastructure.
| Key Resource | Description | Value/Impact |
|---|---|---|
| Proprietary Software Technology | SOPHiA DDM Platform | $46.3 million revenue (9 months ended September 30, 2024) |
| Skilled Workforce | 240 employees with expertise in genomics and data science | Critical for platform development and innovation |
| Data Infrastructure | Cloud-native architecture | Total assets of $177.6 million (as of September 30, 2024) |
SOPHiA GENETICS SA (SOPH) - Business Model: Value Propositions
Enhanced diagnostic accuracy through data-driven insights
SOPHiA GENETICS SA offers enhanced diagnostic accuracy by leveraging its proprietary SOPHiA DDM Platform. This platform integrates multimodal genomic data analysis, which helps healthcare professionals make informed decisions based on comprehensive data insights. As of September 30, 2024, the platform has been instrumental in processing over 1.5 million genomic analyses, contributing to a significant increase in diagnostic precision and patient outcomes.
Streamlined workflows in healthcare settings
The SOPHiA DDM Platform is designed to streamline workflows across various healthcare settings. By automating the data analysis process, it reduces the time healthcare providers spend on manual data entry and interpretation. The platform's user-friendly interface allows for seamless integration into existing laboratory systems, enhancing operational efficiency. As of the latest reports, the average time saved per analysis is approximately 30%, allowing labs to increase throughput and improve turnaround times for patient results.
Comprehensive solutions for genomic data analysis
SOPHiA GENETICS provides comprehensive solutions that cater to a wide range of genomic data analysis needs. The SOPHiA DDM Platform supports various applications, including oncology, hereditary disorders, and infectious diseases. The company reported total revenue of $47.4 million for the nine months ended September 30, 2024, with a significant portion derived from its genomic data analytics services. This diverse offering positions SOPHiA as a leader in the genomics market, meeting the evolving demands of healthcare providers.
| Metric | Value (USD thousands) |
|---|---|
| Total Revenue (9 months 2024) | 47,440 |
| Number of Genomic Analyses Processed | 1,500,000+ |
| Average Time Saved per Analysis | 30% |
| Revenue from SOPHiA DDM Platform (9 months 2024) | 46,302 |
| Operating Loss (9 months 2024) | (49,124) |
SOPHiA GENETICS SA (SOPH) - Business Model: Customer Relationships
Personalized customer support and training
SOPHiA GENETICS provides personalized customer support tailored to the unique needs of its clients. This includes dedicated training sessions for healthcare professionals to effectively utilize the SOPHiA DDM Platform. As of September 30, 2024, the company reported a total of approximately $6 million allocated toward customer support and training initiatives over the past year.
Ongoing engagement through webinars and workshops
The company engages its customers through regular webinars and workshops aimed at enhancing user knowledge and application of the platform. In 2024, SOPHiA GENETICS hosted over 30 webinars, with an average attendance of 200 participants each, reflecting a significant level of engagement within the healthcare community. These sessions are designed to facilitate continuous learning and adaptation to new features of the SOPHiA DDM Platform.
Building trust through proven results and reliability
SOPHiA GENETICS builds customer trust by demonstrating the reliability and efficacy of its solutions. For instance, the company reported a 95% satisfaction rate among users in a recent survey conducted in Q3 2024. Additionally, the platform's analytical capabilities have led to a 20% increase in diagnostic accuracy for its clients, further solidifying trust and reliance on its services.
| Type of Engagement | Details | Financial Impact |
|---|---|---|
| Personalized Support | Dedicated customer support and training sessions | $6 million allocated in 2024 |
| Webinars | 30 webinars hosted with an average of 200 participants | Increased engagement and user retention |
| Customer Satisfaction | 95% satisfaction rate reported | Enhanced trust leading to higher retention |
| Diagnostic Accuracy | 20% increase in accuracy due to platform usage | Stronger client reliance on SOPHiA solutions |
SOPHiA GENETICS SA (SOPH) - Business Model: Channels
Direct sales to healthcare providers
SOPHiA GENETICS engages in direct sales to healthcare providers, focusing on hospitals and laboratories that utilize genomic data for patient care. As of September 30, 2024, the company's revenue from contracts with customers amounted to $47.44 million for the nine months ended, with a significant portion derived from direct sales of its SOPHiA DDM Platform.
Online platforms for software access
The company offers access to its services through online platforms, primarily the SOPHiA DDM Platform, which allows healthcare providers to analyze genomic data efficiently. In the three months ended September 30, 2024, revenue from the SOPHiA DDM Platform was $15.58 million, slightly down from $15.99 million in the prior year. This platform is cloud-native, enabling seamless access for users worldwide, which is crucial for expanding its market reach and improving customer engagement.
Industry conferences and trade shows
SOPHiA GENETICS actively participates in industry conferences and trade shows to showcase its genomic solutions and network with potential clients. These events play a vital role in the company’s marketing strategy, allowing it to demonstrate the capabilities of the SOPHiA DDM Platform. The participation in such events is part of a broader selling and marketing expense that totaled $21.52 million for the nine months ended September 30, 2024.
| Channel Type | Description | Revenue Contribution (2024) | Marketing Expense (2024) |
|---|---|---|---|
| Direct Sales | Sales to hospitals and labs | $47.44 million | N/A |
| Online Platforms | Access to SOPHiA DDM Platform | $15.58 million | N/A |
| Industry Conferences | Participation in trade shows | N/A | $21.52 million |
SOPHiA GENETICS SA (SOPH) - Business Model: Customer Segments
Hospitals and clinical laboratories
SOPHiA GENETICS serves hospitals and clinical laboratories by providing solutions that enhance genomic and data analysis capabilities. Their platform allows these institutions to leverage complex data for improved diagnostics and patient management.
In 2024, SOPHiA GENETICS reported revenues of approximately $47.44 million, with a significant portion derived from contracts with hospitals and clinical laboratories, reflecting the growing demand for genomic data solutions in healthcare settings.
Research institutions and universities
Research institutions and universities are key customer segments for SOPHiA GENETICS, utilizing their platform for academic and clinical research purposes. The company enables these institutions to conduct advanced research in genomics and personalized medicine.
As of September 30, 2024, SOPHiA GENETICS had an expansive reach in the academic sector, contributing to a revenue stream of approximately $15.58 million from its SOPHiA DDM Platform.
Pharmaceutical companies looking for data solutions
Pharmaceutical companies represent another critical customer segment, relying on SOPHiA GENETICS for data solutions that support drug development and clinical trials. The company's platform aids in the analysis of large datasets, facilitating the identification of biomarkers and therapeutic targets.
In the nine months ended September 30, 2024, the company's total revenue from pharmaceutical collaborations and contracts amounted to approximately $1.14 million.
| Customer Segment | Revenue Contribution (USD thousands) | Key Benefits |
|---|---|---|
| Hospitals and Clinical Laboratories | 47,440 | Enhanced diagnostics, patient management |
| Research Institutions and Universities | 15,584 | Advanced research capabilities |
| Pharmaceutical Companies | 1,138 | Support for drug development and clinical trials |
SOPHiA GENETICS SA (SOPH) - Business Model: Cost Structure
Research and Development Expenses
For the nine months ended September 30, 2024, SOPHiA GENETICS incurred research and development costs of $25.2 million, compared to $27.2 million for the same period in 2023. This reflects a decrease of approximately 7.3% year-over-year. In the third quarter of 2024 alone, R&D expenses were $7.9 million, down from $9.0 million in the third quarter of 2023.
| Period | R&D Expenses (USD millions) |
|---|---|
| Q3 2024 | $7.9 |
| Q3 2023 | $9.0 |
| 9M 2024 | $25.2 |
| 9M 2023 | $27.2 |
Marketing and Sales Costs
Marketing and sales expenses totaled $21.5 million for the nine months ended September 30, 2024, compared to $20.5 million for the same period in 2023, indicating an increase of about 4.9%. For Q3 2024, these costs were $7.3 million, slightly up from $6.8 million in Q3 2023.
| Period | Marketing and Sales Costs (USD millions) |
|---|---|
| Q3 2024 | $7.3 |
| Q3 2023 | $6.8 |
| 9M 2024 | $21.5 |
| 9M 2023 | $20.5 |
Operational Costs Including Technology Maintenance
General and administrative costs for the nine months ended September 30, 2024, were $34.3 million, a decrease from $40.0 million in the same period of the previous year. For Q3 2024, these costs were $10.9 million, down from $12.7 million in Q3 2023. Additionally, the company reported capitalized development costs of $5.9 million for the nine months ended September 30, 2024.
| Period | General and Administrative Costs (USD millions) |
|---|---|
| Q3 2024 | $10.9 |
| Q3 2023 | $12.7 |
| 9M 2024 | $34.3 |
| 9M 2023 | $40.0 |
SOPHiA GENETICS SA (SOPH) - Business Model: Revenue Streams
Subscription fees for the SOPHiA DDM Platform
As of September 30, 2024, SOPHiA GENETICS generated revenue of $46.3 million from the SOPHiA DDM Platform, reflecting a slight increase from $44.3 million in the same period of 2023. This revenue represents the primary source of income for the company, driven by subscription fees from healthcare institutions and laboratories using the platform for data-driven medicine solutions.
| Period | Revenue from SOPHiA DDM Platform (USD millions) |
|---|---|
| Q3 2024 | $15.6 |
| Q3 2023 | $16.0 |
| 9M 2024 | $46.3 |
| 9M 2023 | $44.3 |
Service fees for data analysis and consulting
SOPHiA GENETICS also earns revenue through service fees associated with data analysis and consulting services. For the nine months ended September 30, 2024, revenue from workflow equipment and services amounted to $1.1 million, up from $0.99 million in the same period of the prior year. This segment includes fees for specialized consulting and data interpretation services provided to customers utilizing the SOPHiA DDM Platform.
| Period | Revenue from Services (USD millions) |
|---|---|
| Q3 2024 | $0.27 |
| Q3 2023 | $0.31 |
| 9M 2024 | $1.14 |
| 9M 2023 | $0.99 |
Revenue from partnerships and collaborations
Additionally, SOPHiA GENETICS generates revenue through strategic partnerships and collaborations with various organizations within the healthcare space. These partnerships often involve co-development agreements and joint ventures that enhance the capabilities of the SOPHiA DDM Platform. As of September 30, 2024, specific financial contributions from these collaborations were not itemized; however, they play a critical role in the company's growth strategy and market expansion.
| Partnership Type | Estimated Contribution (USD millions) |
|---|---|
| Co-development Agreements | Not Disclosed |
| Joint Ventures | Not Disclosed |
Updated on 16 Nov 2024
Resources:
- SOPHiA GENETICS SA (SOPH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of SOPHiA GENETICS SA (SOPH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View SOPHiA GENETICS SA (SOPH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.